Biliary reflux appears to be associated with gastritis. Although a causal role for duodeno-gastric reflux is reported by several studies, nevertheless, treatment of reflux gastritis is largely unknown. Aluminium-hydroxide-containing antacids and sucralfate, because of their reported capacity to bind bile acids and lysolecithin, may be useful in the treatment of reflux gastritis. Forty-four patients with superficial bile reflux gastritis were randomly treated with either antacids (Maalox® TC, 15 ml QID) or sucralfate (1 gm, TID) or placebo for eight weeks. The presence of dyspeptic symptoms and the grade of endoscopic and histological changes were assessed before treatment and at the end of the study. In all the groups a nonsignificant reduction in the presence of symptoms was observed at eight weeks. Antacids were shown to significantly improve the endoscopic score (P <0.01) and the histological features (P = 0.028), whereas no differences were observed in the sucralfate and placebo groups. In conclusion, aluminium-hydroxide-containing antacids appear to represent an effective therapeutic approach in patients with bile reflux gastritis, not previously submitted to gastric surgery.
|Number of pages||7|
|Journal||Current Therapeutic Research|
|Publication status||Published - 1989|
ASJC Scopus subject areas